Indications for: VIVOTIF
Immunization against typhoid fever.
Limitations of Use:
The vaccine will not afford protection against species of Salmonella other than Salmonella typhi or other bacteria that cause enteric disease.
The vaccine is not suitable for treatment of acute infections with S. typhi.
The efficacy of the S. typhi Ty21a strain has been evaluated in a series of randomized, double-blind, controlled field trials. Vaccine efficacy was found to be highest with the 4 dose regimen.
Because of the very low incidence of typhoid fever in United States citizens, efficacy studies are not currently feasible in this population. It is expected that Vivotif will provide protection to recipients from non-typhoid endemic areas such as the United States.
Adults and Children:
Do not crush or chew. Give 1 hour before a meal with cold or lukewarm (not >body temp) drink. Complete therapy at least 1 week before expected exposure; may repeat every 5yrs. <6yrs: not recommended. ≥6yrs: 1 cap every other day for a total of 4 doses.
Acute febrile or GI illness. Immunocompromised states.
Defer in active infection, fever, persistent diarrhea, or vomiting. Exposure to contaminated food and water should be avoided. Pregnancy. Nursing mothers.
Do not administer in patients receiving sulfonamides and antibiotics. Certain anti-malaria drugs may interfere with immunogenicity.
Nausea, abdominal cramps, vomiting, rash, urticaria (all infrequent and transient).